

1 **Multi-species co-circulation of adenoviruses identified by next generation sequencing**
2 **during an outbreak in coastal Kenya in 2023**

3

4 **Authors**

5 **Arnold W. Lambisia¹, Martin Mutunga¹, Esther N. Katama¹, Charles N. Agoti^{1,2}, Charlotte J.**
6 **Houldcroft³**

7

8 **Affiliations**

- 9 1. KEMRI-Wellcome Trust Research Programme, Epidemiology and Demography
10 Department, Kilifi, Kenya
- 11 2. Pwani University, School of Health and Human Sciences, Kilifi, Kenya
- 12 3. University of Cambridge, Department of Genetics, Downing Street, Cambridge, CB2
13 3EH, United Kingdom

14

15 *Corresponding author:

16 Contact details: P.O. Box 230, Kilifi-80108, Kenya,

17 Email: alambisia@kemri-wellcome.org

18

19 **Key words:** Human adenovirus, ONT, enteric, Kenya, RespiCov

20

21

22 **Abstract (247 words)**

23 **Background**

24 Although seven human adenovirus (HAdV) species are known to exist, only F (types 40 and
25 41) and G, are identified as diarrhoeal disease agents. The role of other HAdV species in
26 diarrhoeal disease remains unclear and data of their prevalence is limited. We describe
27 HAdV species and types in hospitalised children with diarrhoea in coastal Kenya.

28

29 **Methods**

30 329 stool samples collected between June 2022 and August 2023 from children aged <13-
31 years were screened for HAdV using quantitative polymerase chain reaction (qPCR). Positive
32 HAdV cases were genotyped by adenovirus primers from the RespiCoV panel by
33 amplification, next generation sequencing followed by phylogenetic analysis.

34

35 **Results**

36 65 samples (20%) tested HAdV positive from which five HAdV species were identified. Other
37 than HAdV F, other species included A, B, C and D; these were detected as either mono-
38 detections or coinfections. Six HAdV F identified by NGS had been missed by our qPCR
39 typing method. This appeared to be as a result of a 133-nucleotide deletion in the long fiber
40 protein which abrogated a primer and probe binding site. Based on VESIKARI scores grading
41 of diarrheal disease severity, 93% of the HAdV cases presented with severe disease. One
42 child with an HAdV F infection died.

43

44 **Conclusion**

45 Our study shows the enormous diversity and clinical characteristics of HAdV species in
46 children with diarrhoea in coastal Kenya. These data offers an opportunity to improve
47 current diagnostic assays, increase knowledge of HAdV in Africa for control of outbreaks in
48 the future.

49

50

51 **Background (2584 words)**

52 Human adenoviruses (HAdV) are non-enveloped, double-stranded DNA viruses that belong to
53 the *mastadenovirus* genus ¹. To date, seven different species, A to G, and 114 different types
54 of HAdV have been described by the human adenovirus working group
55 (<http://hadvwg.gmu.edu/>). These HAdVs are associated with a variety of diseases
56 presentation including gastroenteritis (F and G) ^{2,3}, respiratory tract infections (A, B, C and E)⁴
57 and keratoconjunctivitis (D) ⁵.

58

59 HAdV types F40 and F41 are a common aetiology of mild to severe diarrhoea among children
60 under the age of five years ^{3,6-11}. However, other HAdV species such as A, B, C, D and E have
61 been detected among diarrhoea cases although their contribution to diarrhoea disease is
62 unclear ^{3,7,10}. In China, HAdV B3 has been associated with diarrhoea (adjusted odds ratio =
63 9.205, $p < 0.001$) ³. In Canada, HAdV F40/41, detections had the highest attributable fraction
64 (96%; 95% confidence interval (C.I), 92.3 to 97.7%) to diarrhoea symptoms compared to
65 species A, B, C and E, but HAdV C1, C2, C5 and C6 were also attributed to 52% (95% C.I, 12 to
66 73%) of the symptoms ¹⁰. A previous study in Kenya reported predominance of HAdV species
67 D and F in urban and rural settings respectively, among cases with diarrhoea; but other types
68 including B3, B21, C2, C5 and C6 were also detected among diarrhoeal cases ¹².

69

70 The KEMRI-Wellcome Trust Research Programme (KWTRP) has been conducting a prospective
71 hospital-based rotavirus surveillance study at Kilifi County Hospital paediatric ward in coastal,
72 Kenya ^{6,13}. The prevalence of adenoviruses of any species among paediatric diarrhoea cases in
73 coastal Kenya has been reported to be 15.9% (95% C.I 12.8 to 19.5). However, HAdV F only
74 accounts for approximately half of the HAdV detections (7.3%, 95% C.I 5.2-10.1) with the rest
75 of the HAdVs untyped ¹³.

76

77 This study aimed to genotype HAdV positive samples detected between June 2022 and August
78 2023 to determine the circulating non-F HAdVs and any HAdV-Fs that may have been missed
79 by real-time PCR screening. HAdV genotyping is typically done by amplifying a region of the
80 hexon gene, followed by Sanger sequencing ¹⁴. Here we used adenovirus primers from the
81 RespiCoV panel ¹⁵, applying these primers to stool-derived nucleic acid extracts for the first
82 time, and sequencing the amplicons on the Oxford Nanopore Technologies (ONT) platform.

83 **Methods**

84 **Study site and population.**

85 The target population was children below the age of 13 years admitted to Kilifi County Hospital
86 (KCH) who presented with diarrhoea as one of their illness symptoms i.e three or more loose
87 stools in a 24-hour period ¹⁶.

88

89 **Laboratory Methods**

90 **Total Nucleic Acid (TNA) Extraction and Screening**

91 TNA was extracted from 0.2 g (or 200 µl if liquid) of stool samples using QIAamp® Fast DNA
92 Stool Mini kit (Qiagen, UK) as previously described. Pan-HAdV (forward primer: 5'-
93 GCCCCAGTGGTCTTACATGCACATC -3'; probe: 'FAM-TCGGAGTACCTGAGCCCGGGTCTGGTGCA-
94 MGBNFQ'; and Reverse primer: 5'-GCCACGGTGGGGTTTCTAAACTT-3') and HAdV-F (forward
95 primer: 5'-CACTTAATGCTGACACGGGC-3'; probe: 'FAM-TGCACCTCTTGGACTAGT-MGBNFQ';
96 and Reverse primer: 5'-ACTGGATAGAGCTAGCGGGC-3') primers and probes, and TaqMan Fast
97 Virus 1-Step Master Mix were used for screening as previously described ¹⁷. The thermocycling
98 conditions were 95°C for 20 seconds and 35 cycles of 94°C for 15 seconds and 60°C for
99 30 seconds.

100

101 **DNA amplification**

102 The primers used in amplification were adopted from the RespiCov panel ¹⁵. Briefly, 14
103 adenovirus primers were pooled into one tube and resuspended in nuclease free water to
104 generate a 10µM working concentration. TNA from HAdV positive samples were amplified
105 using the Q5® Hot Start HighFidelity 2X Master Mix (NEB) kit. The master mix was prepared as
106 follows: Q5® Hot Start High-Fidelity 2X Master Mix (6.25 µl), H2O (3 µl), HAdV Primer pool (2
107 µl), and DNA (1.25 µl). The reaction was then incubated on a thermocycler using the following
108 conditions: 98°C for 30 seconds followed by 35 cycles of 98°C for 15 seconds, 65°C for 30
109 seconds and 72°C for 20 seconds and a final extension of 72°C for 5 minutes.

110

111 **Library Preparation and Oxford Nanopore Technologies (ONT) Sequencing**

112 Library preparation was performed using the SQK-LSK114 ligation kit with SQK-NBD114.96
113 barcoding kit. Briefly, the amplicons were end-repaired, barcoded, and pooled into one tube,

114 and adapters ligated to the library and the final library sequenced using the FLOW-MIN106D
115 R9.4.1 flow cell on the GridION platform (ONT) for one hour.

116

117 Long Fiber amplification and Illumina sequencing

118 Primers that could amplify the long fiber protein were obtained by picking forward (HAdV-
119 F41_1kb_jh_85_LEFT:ACACTACAMTCCCCTTGACATCC) and reverse primers (HAdV-
120 F41_1kb_jh_87_RIGHT:AAGAAAATGAGCAGCAGGGGATG) from the whole genome
121 sequencing HAdV primers designed elsewhere ([Quick F41 WGS primers](#)). The mastermix
122 reaction was prepared as described in the above section and incubated on a thermocycler
123 using the following conditions: 98°C for 30 seconds followed by 35 cycles of 98°C for
124 15 seconds and 65°C for 5 minutes. The amplicons generated were used for library
125 preparation using an Illumina library preparation kit as recommended by the manufacturer.
126 Briefly, the amplicons were tagmented, indexed, and amplified. The libraries were then
127 normalized, pooled, and sequenced as paired-end reads (2*150 bp).

128

129 Data analysis

130 Genotyping

131 The FASTQ reads from the GridION were trimmed using porechop v.0.2.4 and mapped to the
132 HAdV reference genomes (DQ923122.2, NC_001460.1, NC_001454.1, NC_001405.1,
133 AC_000006.1, AC_000018.1, AC_000008.1, NC_012959.1) using minimap2 v.2.24-r1122
134 (<https://github.com/lh3/minimap2>). Variant calling and consensus sequence generation was
135 done using ivar v.1.3.1 (<https://github.com/andersen-lab/ivar>) with a minimum read depth of
136 20. Taxonomic classification was done using BLASTN (<https://blast.ncbi.nlm.nih.gov/>).

137

138 The generated consensus genomes were aligned with contemporaneous global HAdV
139 sequences on GenBank using MAFFT (<https://mafft.cbrc.jp/alignment/software/>) and
140 maximum likelihood trees generated using iqtree 2 (<http://www.iqtree.org/>). The trees were
141 then annotated and visualized using ggtree
142 (<https://guangchuangyu.github.io/software/ggtree>).

143

144 Long fiber primer check validation

145 Short-read paired fastq data obtained from the Illumina MiSeq platform was trimmed using
146 fastp with a phred score of q30. The cleaned reads were then mapped to the HAdV-F
147 reference genome using bwa (<https://github.com/lh3/bwa>). The primers were then trimmed
148 from the BAM files and consensus genomes generated using ivar.

149

150 For quality check, the cleaned reads were also assembled using a denovo approach using
151 MetaSPAdes v3.13 (<http://cab.spbu.ru/software/spades>). The generated contigs were
152 compared with consensus genomes from the reference guide approach.

153

154 Real-time PCR primer and probe sequences were then aligned to the generated consensus
155 long fiber sequences to check for differences in binding sites using Geneious Prime® 2023.2.1
156 (<https://www.geneious.com>).

157

158 Disease severity

159 The Vesikari Clinical Severity Scoring System Manual was used to estimate disease severity
160 as previously described¹⁸. The following parameters were used: maximum number of stools
161 and vomiting per day, duration of diarrhoea and vomiting episodes in days, temperature,
162 dehydration status and treatment. The Vesikari grading categories were mild, moderate, and
163 severe for scores of <7, 7-10 and ≥ 11 respectively.

164


165 **Results**

166 **HAdV Epidemiology**

167 Between 3rd June 2022 and 28th August 2023, 329 children with diarrhoea as one of their
168 illness symptoms were consented and gave stool samples for enteric viruses screening. A total
169 of 65 (20%) cases had a HAdV detection in their sample when using a pan-adenovirus real-
170 time PCR assay. Forty-three samples were successfully sequenced and genotyped using
171 adenovirus RespiCoV primers to determine the circulating HAdV species and types in stool.

172

173 Single or multiple HAdV types were detected in the samples (**Figure 1**). Single HAdV type
174 detections were as follows: F (n=13), C (n=12), D (n=3), B (n=2) and A (n=2). Codetection of
175 HAdV samples was also observed in 10 samples: C and F (n=4), A and C (n=3), A and D (n=1),
176 F and D (n=1), and C, F and D (n=1) (**Figure 1B**).




177

178 **Figure 1:** Temporal distribution of human adenoviruses in coastal Kenya between June 2022
 179 and August 2023. A) Temporal plot showing distribution of F, mixed F (F and non-F
 180 coinfections) and non-F. The primary y axis shows the proportions of adenovirus species while
 181 the secondary y axis shows the total number of diarrhoea monthly cases. B) Temporal plot
 182 showing the distribution of HAAdV species between June 2022 and August 2023.

183

184 The HAAdV species were further characterized into types (**Figure 2**). Both HAAdV F40 (n=7) and
 185 F41 (n=13) were detected in HAAdV species F-positive cases. Within HAAdV species A, A31 (n=4),
 186 A18 (n=2) and A12 (n=1) were identified. Only HAAdV B7 was identified in species B. HAAdV type
 187 C1 (n=5), C2 (n=5), C5 (n=5) and C89 (n=5) were identified within species HAAdV C. Within HAAdV
 188 D, D54 was identified in two samples while the rest of the sequences could not be genotyped
 189 further phylogenetically (**Figure 2**).

190



191

192 **Figure 2:** Maximum likelihood trees showing the divergence of detected HAdV types A)

193 HAdV A B) HAdV B C) HAdV C D) HAdV D54 E) HAdV D* and F) HAdV F.

194

195 **Adenovirus outbreak in May 2023**

196 In May 2023, there was a noticeable increase in adenovirus detections among children
 197 presenting with diarrhoea over the study period. From the 13 HAdV cases in May 2023, 69%
 198 of the cases were genotyped as non-HAdV F (D (n=3), B (n=2), C (n=2), A and C (n=1) and A
 199 (n=1)) and only 4 samples were genotyped as HAdV F. Notably, 38% of the 13 HAdV cases had
 200 coinfections with norovirus GII (n=4) and astrovirus (n=1).

201

202 **Demographic and clinical characteristics of HAdV cases**

203 The majority of the HAdV cases were male (60.5%) and between the age of 12 to 59 months
 204 (65.1%). Coinfections with rotavirus A, norovirus GII, sapovirus and astrovirus were identified
 205 across the different HAdV species. Majority of the cases (93%) presented with severe disease,
 206 including all the non-F cases (**Table 1**). Only one fatality was identified in the HAdV F cases and
 207 none in the non-F cases (**Table 1**).

208

209

210 **Table 1:** Demographic and clinical characteristics of HAdV genotyped cases in coastal Kenya

	HAdV F (n=13)	HAdV Codetection F and non- F (n=7)	HAdV non-F (n=23)	Total (n=43)
Sex				
Female	7 (53.8%)	2 (28.6%)	6 (26.1%)	15 (34.9%)
Male	6 (46.2%)	4 (57.1%)	16 (69.6%)	26 (60.5%)
No data	0 (0.0%)	1 (14.3%)	1 (4.3%)	2 (4.7%)
Age (Months)				
Median (interquartile range)	13 (7 – 21)	11.5 (11-28.5)	15.5 (10.2-20)	14 (10-21)
Age group (months)				
<12	1 (7.7%)	2 (28.6%)	3 (13.0%)	6 (14.0%)
12 - 23	5 (38.5%)	1 (14.3%)	9 (39.1%)	15 (34.9%)
24 - 59	5 (38.5%)	2 (28.6%)	6 (26.1%)	13 (30.2%)
≥60	2 (15.4%)	2 (28.6%)	5 (21.7%)	9 (20.9%)
Coinfections				
Rotavirus A	1 (7.7%)	2 (28.6%)	3 (13.0%)	6 (14.0%)
Norovirus GII	0 (0.0%)	1 (14.3%)	4 (17.4%)	5 (11.6%)
Sapovirus	1 (7.7%)	0 (0.0%)	2 (8.7%)	3 (7.0%)
Astrovirus	0 (0.0%)	1 (14.3%)	0 (0.0%)	1 (2.3%)
Disease severity				
Moderate	2 (15.4%)	1 (14.3%)	0 (0.0%)	3 (7.0%)
Severe	11 (84.6%)	6 (85.7%)	23 (100.0%)	40 (93.0%)
Outcome				
Alive	12 (92.3%)	6 (85.7%)	22 (95.7%)	40 (93.0%)
Dead	1 (7.7%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
No data	0 (0.0%)	1 (14.3%)	1 (4.3%)	2 (4.7%)

211

212 **Failure of HAdV-F real-time PCR Assay**

213 The genotyping results detected six additional HAdV-F positives that were missed by real-time
 214 PCR. Successful sequencing of the long fiber protein where the real-time PCR primers bind
 215 showed that the sequences had a 133 base deletion that spanned the forward primer and
 216 probe binding regions leading to failure in the HAdV-F real-time PCR assay (**Figure 3**).

	Forward Primer	Probe	Reverse Primer
	C A C T T A A T G C T G A C A C G G G C	T G C A C C T C T T G G A C T A G T	G C C C G C T A G C T C T A T C C A G T
KE_HdAV_S1	N N N N N N N N N N N N N N N N N N	N N N N N N N N N N N N N N N N N N
KE_HdAV_S2	N N N N N N N N N N N N N N N N N N	N N N N N N N N N N N N N N N N N N
KE_HdAV_S3	N N N N N N N N N N N N N N N N N N	N N N N N N N N N N N N N N N N N N
KE_HdAV_S4	N N N N N N N N N N N N N N N N N N	N N N N N N N N N N N N N N N N N N
KE_HdAV_S5	N N N N N N N N N N N N N N N N N N	N N N N N N N N N N N N N N N N N N
KE_HdAV_S6	N N N N N N N N N N N N N N N N N N	N N N N N N N N N N N N N N N N N N
KE_HdAV_S7
KE_HdAV_S8
KE_HdAV_S9
KE_HdAV_S10
KE_HdAV_S11
KE_HdAV_S12

217


218 **Figure 3:** An alignment of HAdV F sequences from missed and detected HAdV F samples
 219 mapped to the primers and probe sequences. Dots show consensus and Ns show gaps in the
 220 primer and probe binding sites.

221

222 **Ct Value distribution**

223 HAdV F cases had significantly lower Ct values compared to non-F cases ($p = 0.002$) (**Figure 4**).
 224 There was no significant difference in Ct value among HAdV F cases and cases that had
 225 codetections of HAdV-F and non-F. Eight non-F cases had a Ct value of less than 25 (high viral
 226 load) but six of these samples also had coinfections with norovirus GII, rotavirus A and
 227 sapovirus.

228



229

230 **Figure 4:** Comparison of HAdV viral load (inverse of cycle threshold value) among F, mixed F
 231 (coinfection of F and non-F) and non-F cases.

232 Discussion

233 The study findings show that multiple HAdV species and types were in circulation between
234 June 2022 and August 2023 in coastal Kenya and that our current real-time PCR primers for
235 detecting HAdV F may be missing positive cases due to a 133-nucleotide deletion in the long
236 fiber protein which abolishes a primer and probe binding site in some circulating variants. This
237 is the first application of the adenovirus part of the RespiCov method to stool samples for
238 genotyping enteric viral infections. Previous studies from China, Tunisia, Kenya and Brazil have
239 reported detection of non-F HAdVs similar to our findings ^{3,7,9,10,12,19,20}. Non-F types such as
240 B3, C1, C2, C5 and C6 have been associated with increased risk of diarrhoea but direct
241 causation is not yet clear ^{3,10}. In this study, we did not detect HAdV B3 but detected the HAdV
242 types C1 and C5; although we cannot conclude that they were the main cause of diarrhoea in
243 these individuals. The RespiCov method used could not clearly genotype all HAdV species D
244 phylogenetically. This is likely due to the relatively short ~300 base pair hexon region that is
245 amplified and the highly recombinatorial nature of species D HAdVs within the hexon locus ²¹.

246
247 Within HAdV F, there is a high divergence in the strains that have been reported to be
248 circulating in Kenya and other regions across the globe ^{17,22-24}. If this divergence occurs in
249 primer and probe binding sites, nucleic acid amplification methods used for detection may be
250 affected. The genotyping results in this study showed six HAdV F cases were missed by the F-
251 specific real-time PCR assay. Amplification of the long fiber protein revealed a 133 base
252 deletion that impacted the HAdV-F real-time PCR assay, and it is advisable that similar primers
253 used in previous works ^{13,17} may be missing some positives and need redesigning, a
254 phenomenon previously seen in SARS-CoV-2 ²⁵, HIV ²⁶ and *Chlamydia trachomatis* ²⁷.

255
256 HAdV F samples had a significantly higher viral load (lower Ct value) compared to non-F
257 samples, similar to previous studies ^{10,19}. HAdV species F is highly associated with diarrhoea
258 when the Ct value is below 22.7 and cases and controls can be discriminated at Ct 30.5
259 suggesting that the HAdV F detected in this study may be clearly associated with diarrhoea
260 ^{9,28}. Interestingly, the HAdV-F detections with Ct value above 30 had a rotavirus A coinfection
261 suggesting that they could be the secondary cause of diarrhoea. The non-F HAdVs detected
262 had a lower viral load and were detected with other enteric viruses including rotavirus A,
263 norovirus GII and sapovirus suggesting that they may be associated with carriage due to

264 prolonged shedding or gut contamination from respiratory infections rather than diarrhoea
265 ^{29,30}.

266

267 This study had some limitations. First, there was no clinical data on the respiratory symptoms
268 of the patients to help interpret the non-enteric HAdVs detected in stool samples which are
269 usually associated with respiratory illnesses. Secondly, only four common enteric viruses were
270 screened for, and these were frequently detected as coinfections in non-F cases. Screening for
271 additional causes such as bacteria, parasites and helminths may have helped elucidate
272 whether other enteric pathogens contribute to the detection of non-F cases.

273

274 In conclusion, there is a high diversity of HAdV types found among diarrhoea cases in coastal
275 Kenya and this may reflect the situation in Africa where there is limited data. Timely and
276 accurate genotyping of these HAdV cases is key for troubleshooting failure of molecular
277 detection assays, estimation of diarrhoea prevalence associated with HAdV-F and
278 implementation of interventions to reduce the burden of HAdV associated diarrhoea.

279 **Declarations**

280 **Ethics approval and consent to participate.**

281 The research protocol for the study was approved at Kenya Medical Research Institute
282 (KEMRI), by the Scientific and Ethics Review Unit (SSC#2861) in Nairobi, Kenya.

283

284 **Acknowledgement**

285 We are grateful to the study participants who provided samples and members of the
286 pathogen epidemiology and omics group at KEMRI-Wellcome Trust Programme who did
287 sample collection and laboratory processing. This manuscript was written with the
288 permission of Director KEMRI CGMRC.

289

290 **Funding.**

291 This study was funded in part by the Cambridge-Africa ALBORADA Research Fund to Drs Agoti
292 and Houldcroft. This research was funded in part by the Wellcome Trust [226002/Z/22/Z].

293 For the purpose of Open Access, the author has applied a CC-BY public copyright license to
294 any author accepted manuscript version arising from this submission.

295

296 **Competing interests**

297 The authors declare no conflict of interest.

298

299 **Data availability**

300 The datasets used and/or analyzed during the current study are available from the KWTRP

301 Research repository via <https://doi.org/10.7910/DVN/XCHBND>. The HAdV sequences were

302 deposited on GenBank and can be accessed using the accession numbers PP318651-

303 PP318703.

304

305 **Authors' contributions**

306 CAN and CJH sourced the study funding. CNA, CJH and AWL designed the study laboratory

307 assay. AWL and MM did the laboratory experiments. EK and AWL managed the study data

308 and did the data analysis. AWL, CAN and CJH wrote the first manuscript draft. All authors

309 read, revised, and approved the final manuscript.

References

1. Hulo C, de Castro E, Masson P, Bougueleret L, Bairoch A, Xenarios I, et al. ViralZone: a knowledge resource to understand virus diversity. *Nucleic Acids Res [Internet]*. 2011 Jan 1 [cited 2023 Dec 19];39(suppl_1):D576–82. Available from: <https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkq901>
2. Bányai K, Martella V, Meleg E, Kisfali P, Peterfi Z, Benkö M, et al. Searching for HAdV-52, the putative gastroenteritis-associated human adenovirus serotype in Southern Hungary. *New Microbiol*. 2009;32(2):185–8.
3. Qiu F zhou, Shen X xin, Li G xia, Zhao L, Chen C, Duan S xia, et al. Adenovirus associated with acute diarrhea: A case-control study. *BMC Infect Dis*. 2018;18(1):1–7.
4. Lynch J, Kajon A. Adenovirus: Epidemiology, Global Spread of Novel Serotypes, and Advances in Treatment and Prevention. *Semin Respir Crit Care Med [Internet]*. 2016 Aug 3;37(04):586–602. Available from: <http://www.thieme-connect.de/DOI/DOI?10.1055/s-0036-1584923>
5. Adhikary AK, Banik U. Human adenovirus type 8: The major agent of epidemic keratoconjunctivitis (EKC). *J Clin Virol [Internet]*. 2014 Dec;61(4):477–86. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1386653214004028>
6. Lambisia AW, Murunga N, Mutunga M, Cheruiyot R, Maina G, Makori TO, et al. Temporal changes in the positivity rate of common enteric viruses among paediatric admissions in coastal Kenya, during the COVID-19 pandemic, 2019–2022. *Gut Pathog [Internet]*. 2024 Jan 4;16(1):2. Available from: <https://gutpathogens.biomedcentral.com/articles/10.1186/s13099-023-00595-4>
7. Afrad MH, Avzun T, Haque J, Haque W, Hossain ME, Rahman AFMR, et al. Detection of enteric- and non-enteric adenoviruses in gastroenteritis patients, Bangladesh, 2012–2015. *J Med Virol*. 2018;90(4):677–84.
8. Ghebremedhin B. Human adenovirus: Viral pathogen with increasing importance. *Eur J Microbiol Immunol*. 2014;4(1):26–33.
9. Huang Z, He Z, Wei Z, Wang W, Li Z, Xia X, et al. Correlation between prevalence of selected enteropathogens and diarrhea in children: A case-control study in China. *Open Forum Infect Dis*. 2021;8(10):1–7.
10. Pabbaraju K, Tellier R, Pang XL, Xie J, Lee BE, Chui L, et al. A Clinical Epidemiology and

- Molecular Attribution Evaluation of Adenoviruses in Pediatric Acute Gastroenteritis: a Case-Control Study on behalf of the Alberta Provincial Pediatric Enteric Infection TEam (APPETITE). 2020;(December):1–11. Available from:
<https://doi.org/10.1128/JCM.02287>
11. Binder AM, Biggs HM, Haynes AK, Chommanard C, Lu X, Dean ;, et al. Morbidity and Mortality Weekly Report Human Adenovirus Surveillance-United States, 2003-2016. *MMWR Morb Mortal Wkly Rep.* 2017;66(39):1039–1042.
 12. Magwalivha M, Wolfaardt M, Kiulia NM, van Zyl WB, Mwenda JM, Taylor MB. High prevalence of species D human adenoviruses in fecal specimens from Urban Kenyan children with diarrhea. *J Med Virol [Internet]*. 2010 Jan;82(1):77–84. Available from:
<https://onlinelibrary.wiley.com/doi/10.1002/jmv.21673>
 13. Agoti CN, Curran MD, Murunga N, Ngari M, Muthumbi E, Lambisia AW, et al. Differences in epidemiology of enteropathogens in children pre- and post-rotavirus vaccine introduction in Kilifi, coastal Kenya. *Gut Pathog [Internet]*. 2022 Dec 1;14(1):32. Available from:
<https://gutpathogens.biomedcentral.com/articles/10.1186/s13099-022-00506-z>
 14. Lu X, Erdman DD. Molecular typing of human adenoviruses by PCR and sequencing of a partial region of the hexon gene. *Arch Virol.* 2006;151(8):1587–602.
 15. Brinkmann A, Uddin S, Ulm SL, Pape K, Förster S, Enan K, et al. RespiCoV: Simultaneous identification of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and 46 respiratory tract viruses and bacteria by amplicon-based Oxford-Nanopore MinION sequencing. *PLoS One.* 2022;17(3 March):1–11.
 16. World Health organization - WHO. The Treatment of diarrhoea : a manual for physicians and other senior health workers. -- 4th rev [Internet]. Vol. 17. 2005 [cited 2023 Oct 2]. p. 562–3. Available from:
<https://www.who.int/publications/i/item/9241593180>
 17. Lambisia AW, Makori TO, Mutunga M, Cheruiyot R, Murunga N, Quick J, et al. Genomic epidemiology of human adenovirus F40 and F41 in coastal Kenya: A retrospective hospital-based surveillance study (2013-2022). *Virus Evol.* 2023;9(1):vead023.
 18. Lewis K. *VAD_vesikari_scoring_manual.pdf*. 2011.
 19. do Nascimento LG, Fialho AM, de Andrade J da SR, de Assis RMS, Fumian TM. Human

- enteric adenovirus F40/41 as a major cause of acute gastroenteritis in children in Brazil, 2018 to 2020. *Sci Rep* [Internet]. 2022;12(1):1–12. Available from: <https://doi.org/10.1038/s41598-022-15413-1>
20. Bouazizi A, Ben Hadj Fredj M, Bennour H, Jerbi A, Ouafa kallala, Fodha I, et al. Molecular analysis of adenovirus strains responsible for gastroenteritis in children, under five, in Tunisia. *Heliyon* [Internet]. 2024;10(1):e22969. Available from: <https://doi.org/10.1016/j.heliyon.2023.e22969>
 21. Walsh MP, Chintakuntlawar A, Robinson CM, Madisch I, Harrach B, Hudson NR, et al. Evidence of Molecular Evolution Driven by Recombination Events Influencing Tropism in a Novel Human Adenovirus that Causes Epidemic Keratoconjunctivitis. Markotter W, editor. *PLoS One* [Internet]. 2009 Jun 3;4(6):e5635. Available from: <https://dx.plos.org/10.1371/journal.pone.0005635>
 22. Götting J, Cordes AK, Steinbrück L, Heim A. Molecular Phylogeny of human adenovirus type 41 lineages. *bioRxiv* [Internet]. 2022;2022.05.30.493978. Available from: <https://www.biorxiv.org/content/10.1101/2022.05.30.493978v1%0Ahttps://www.biorxiv.org/content/10.1101/2022.05.30.493978v1.abstract>
 23. Chandra P, Lo M, Mitra S, Banerjee A, Saha P, Okamoto K, et al. Genetic characterization and phylogenetic variations of human adenovirus-F strains circulating in eastern India during 2017–2020. *J Med Virol* [Internet]. 2021 Nov 29;93(11):6180–90. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/jmv.27136>
 24. Maes M, Khokhar F, Wilkinson SA, Smith A, Kovalenko G, Dougan G, et al. Enteric adenovirus F41 genetic diversity comparable to pre-COVID-19 era: validation of a multiplex amplicon-MinION sequencing method. *OSFPREPRINTS* [Internet]. 2022;Preprint:1–23. Available from: <https://osf.io/6jku5>
 25. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. *Nature* [Internet]. 2021 May 13;593(7858):266–9. Available from: <https://www.nature.com/articles/s41586-021-03470-x>
 26. Müller B, Nübling CM, Kress J, Roth WK, De Zolt S, Pichl L. How safe is safe: new human immunodeficiency virus Type 1 variants missed by nucleic acid testing. *Transfusion* [Internet]. 2013 Oct 17;53(10pt2):2422–30. Available from:

<https://onlinelibrary.wiley.com/doi/10.1111/trf.12298>

27. Ripa T, Nilsson PA. A Chlamydia trachomatis Strain With a 377-bp Deletion in the Cryptic Plasmid Causing False-Negative Nucleic Acid Amplification Tests. Sex Transm Dis [Internet]. 2007 May;34(5):255–6. Available from: <https://journals.lww.com/00007435-200705000-00001>
28. Liu J, Platts-Mills JA, Juma J, Kabir F, Nkeze J, Okoi C, et al. Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study. Lancet. 2016;
29. Bartholomeusz A, Locarnini S. Associated With Antiviral Therapy. Antivir Ther. 2006;55(November 2005):52–5.
30. Kim JS, Lee SK, Ko DH, Hyun J, Kim HS, Song W, et al. Associations of adenovirus genotypes in Korean acute gastroenteritis patients with respiratory symptoms and intussusception. Biomed Res Int. 2017;2017.